Skip to main
IGC

IGC Stock Forecast & Price Target

IGC Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

IGC Pharma is a clinical-stage pharmaceutical company focused on developing cannabinoid-based therapies for the treatment of Alzheimer's disease (AD). With 5 novel drug candidates targeting AD, including two in later stages of development and promising data from its ongoing CALMA clinical trial, the company has a positive outlook. Additionally, the recent change in fiscal year and upcoming milestones, including the completion of the CALMA trial and release of its AI beta program, could serve as catalysts for the stock. Despite potential risks, such as balance sheet and liquidity concerns, the company has significant market potential as there are currently no known cures or effective treatments for AD, a leading cause of dementia impacting millions of Americans.

Bears say

IGC Pharma is facing significant risks in achieving its goal, including balance sheet and liquidity risks, failure of product candidates in clinical trials, and challenges in gaining regulatory approval and commercialization. While the company has 5 drug candidates for Alzheimer's disease, its current valuation is primarily based on a single drug, IGC-AD1, which is still in clinical trials and may not be successful in addressing agitation in dementia. There are also concerns about competition and changing macroeconomic factors, making the stock a high-risk investment with uncertain upside potential.

IGC has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About India Globalization Capital (IGC) Forecast

Analysts have given IGC a Strong Buy based on their latest research and market trends.

According to 1 analysts, IGC has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

India Globalization Capital (IGC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.